Analysts See $-0.25 EPS for Endologix, Inc. (ELGX)

October 13, 2018 - By Richard Conner

Endologix, Inc. (NASDAQ:ELGX) LogoInvestors sentiment increased to 1.35 in Q2 2018. Its up 0.49, from 0.86 in 2018Q1. It is positive, as 3 investors sold Endologix, Inc. shares while 31 reduced holdings. 19 funds opened positions while 27 raised stakes. 77.82 million shares or 4.16% less from 81.20 million shares in 2018Q1 were reported.
Fincl Bank Of Montreal Can accumulated 2,733 shares. Swiss Retail Bank has invested 0% of its portfolio in Endologix, Inc. (NASDAQ:ELGX). Brown Capital Mgmt Ltd Liability Corporation invested in 8.78 million shares or 0.51% of the stock. Bancorporation Of America De has 0% invested in Endologix, Inc. (NASDAQ:ELGX). Partner Investment Management Limited Partnership has invested 0.38% in Endologix, Inc. (NASDAQ:ELGX). Metropolitan Life Insurance Ny owns 29,030 shares. Aperio Group Ltd Llc holds 0% of its portfolio in Endologix, Inc. (NASDAQ:ELGX) for 17,503 shares. Tower Limited Liability Corp (Trc) holds 0% or 3,189 shares. California Employees Retirement System reported 91,000 shares. Susquehanna Grp Inc Llp owns 0% invested in Endologix, Inc. (NASDAQ:ELGX) for 41,684 shares. Jpmorgan Chase & has 23,272 shares for 0% of their portfolio. Wellington Management Llp has invested 0% of its portfolio in Endologix, Inc. (NASDAQ:ELGX). Great West Life Assurance Can has invested 0% of its portfolio in Endologix, Inc. (NASDAQ:ELGX). Blackrock has invested 0% in Endologix, Inc. (NASDAQ:ELGX). Moreover, Bluecrest Cap Mngmt Limited has 0% invested in Endologix, Inc. (NASDAQ:ELGX) for 10,444 shares.

Since May 29, 2018, it had 1 buying transaction, and 1 insider sale for $72,809 activity. Mahboob Vaseem had bought 30,000 shares worth $72,900.

Analysts expect Endologix, Inc. (NASDAQ:ELGX) to report $-0.25 EPS on November, 6.They anticipate $0.14 EPS change or 127.27 % from last quarter’s $-0.11 EPS. After having $-0.18 EPS previously, Endologix, Inc.’s analysts see 38.89 % EPS growth. The stock decreased 1.79% or $0.03 during the last trading session, reaching $1.65. About 479,296 shares traded. Endologix, Inc. (NASDAQ:ELGX) has declined 55.38% since October 14, 2017 and is downtrending. It has underperformed by 71.00% the S&P500.

Endologix, Inc. (NASDAQ:ELGX) Ratings Coverage

Among 4 analysts covering Endologix Inc (NASDAQ:ELGX), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Endologix Inc had 4 analyst reports since April 25, 2018 according to SRatingsIntel. The rating was maintained by BMO Capital Markets with “Market Perform” on Monday, August 13. PiperJaffray downgraded the shares of ELGX in report on Friday, August 10 to “Neutral” rating. Stifel Nicolaus maintained Endologix, Inc. (NASDAQ:ELGX) on Monday, May 21 with “Hold” rating.

Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company has market cap of $139.77 million. It offers minimally-invasive endovascular repair products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system. It currently has negative earnings. The firm also provides endovascular sealing (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens.

More important recent Endologix, Inc. (NASDAQ:ELGX) news were published by: Seekingalpha.com which released: “Endologix sees Q3 revenue as high as $34.7M; shares up 1% after hours” on October 02, 2018, also Seekingalpha.com published article titled: “Key events next week – healthcare”, Streetinsider.com published: “Pre-Open Movers 10/03: (ELGX) (JCP) (TPX) Higher; (DTEA) (CENX) (KALA) Lower (more…)” on October 03, 2018. More interesting news about Endologix, Inc. (NASDAQ:ELGX) was released by: Businesswire.com and their article: “FDA Classifies Previous Endologix AFX Safety Notice as Class I Recall” with publication date: October 05, 2018.

Endologix, Inc. (NASDAQ:ELGX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>